[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"miscarriage-in-first-trimester\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:miscarriage-in-first-trimester":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,86,116,140,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642438","grace---genetic-insights-into-early-pregnancy-loss-using-cell-free-fetal-dna-100642438",false,"NCT07639333","GRACE - Genetic Insights Into Early pRegnancy Loss Using Cell-free fEtal DNA","GRACE - Genetic Insights Into Early pRegnancy Loss: A Prospective Study Using Cell-free fEtal DNA","GRACE","Inclusion Criteria:\n\n* A stopped pregnancy with an intrauterine pregnancy diagnosed by ultrasound (embryo larger than 7 mm corresponding to a gestational age of 6 weeks and 5 days. This is justified by the fact that fetal fragment (FF) detection is possible at 5 weeks of gestation, or 7 weeks and 5 days)\n* Expulsion of a pregnancy within the last 2 hours\n\n  * Patient fluent in French\n  * Enrolled in a social security program\n  * Has received oral and written information about the protocol and has signed a consent form to participate in this research.\n\nExclusion Criteria:\n\n* Diagnosis of an empty gestational sac, ectopic pregnancy, or unknown location\n* Ultrasound findings consistent with a molar pregnancy\n* Identified cause (preimplantation diagnosis, multiple uterine fibroids or a single fibroid \\> 5 cm, uterine malformation affecting the uterine cavity, lupus, and antiphospholipid syndrome)\n* Inability to obtain a blood sample\n* Known current malignant tumor\n* Blood transfusions within the last 3 months\n* Cell therapy or immunotherapy within the last 3 months\n* Previous organ transplant","FEMALE","18 Years","43 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this study is to assess the impact of non-invasive prenatal testing right after an early isolated miscarriage on mental health and on the patient's subsequent care in the year following the miscarriage",[28,29],"Miscarriage in First Trimester","Prenatal Genetic Diagnosis",[31,32,33,34,35,36],"early miscarriage","miscarriage","prenatal diagnosis","prenatal test","cell free fetal DNA","chromosomal abnomarlities","NOT_YET_RECRUITING","2026-06-10",{"date":40,"type":41},"2026-06-12","ACTUAL",{"date":43,"type":22},"2026-07",{"date":45,"type":22},"2029-01",{"name":47,"class":48},"Rennes University Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100615531","comprehensive-assessment-of-first-trimester-pregnancy-loss-100615531","NCT07293819","Comprehensive Assessment of First Trimester Pregnancy Loss","Comprehensive Assessment of First Trimester Pregnancy Loss: Analyzing Its Impact and Biological Pathways to Develop Tailored Management Care Strategies (The FIRST-CARE Study)","FIRST-CARE","Female participants:\n\nInclusion Criteria:\n\n* Women aged 18 years or older.\n* Diagnosis of missed miscarriage in the first trimester (\\\u003C14 weeks of gestation) confirmed by ultrasound.\n* Presence of an intrauterine pregnancy with fetal demise (clinical pregnancy loss).\n* Willing and able to provide written informed consent.\n* Ability to understand and complete study procedures.\n\nExclusion Criteria:\n\n* Multiple pregnancy (twins or more).\n* Ectopic pregnancy.\n* Molar pregnancy (complete or partial hydatidiform mole).\n* Ongoing pregnancy with fetal cardiac activity.\n* Inability or unwillingness to comply with study procedures or follow-up.\n\nMale participants: no specific inclusion or exclusion criteria will apply to male partners, since the main inclusion criteria is a clinical pregnancy loss.",{"count":59,"type":22},225,"12 Months","OBSERVATIONAL","The FIRST-CARE Study is a prospective research project conducted at Hospital de la Santa Creu i Sant Pau (Barcelona, Spain), aimed at better understanding the causes and consequences of first-trimester pregnancy loss (miscarriage).\n\nMiscarriage is a common event that affects about 15% of clinically recognized pregnancies and can have both physical and emotional consequences for women and their partners. However, many questions about its causes remain unanswered, and most women do not receive a clear explanation or personalized support after experiencing a loss.\n\nThis study will include 225 women who have experienced a miscarriage during the first 14 weeks of pregnancy. Two groups will be studied: those who have had a miscarriage for the first time and those with a history of recurrent pregnancy loss (defined as two or more previous miscarriages). The aim is to investigate a wide range of possible causes - including genetic, hormonal, immune, cardiovascular, placental, and psychological factors - in order to improve diagnosis and develop more personalized care strategies.\n\nParticipants will undergo a comprehensive evaluation including ultrasound, blood tests, genetic testing, and psychological assessments. In some cases, their partners will also be invited to participate. Women will be followed for one year to assess their mental well-being and reproductive outcomes, such as the chance of getting pregnant again and the outcome of future pregnancies.\n\nThe study will also create a biobank of biological samples to support future research in the field of pregnancy loss.\n\nBy combining clinical evaluations, laboratory tests, and personal experiences, this study aims to uncover new insights into why miscarriages happen and how to better support women and couples going through this experience. The ultimate goal is to provide better diagnostic tools, care pathways, and support systems to reduce the emotional burden of miscarriage and improve reproductive health outcomes.",[28],[65,66,67,68,69,70,71,72,73,74],"Miscarriage","First-trimester","Genetic testing","angiogenic markers","pregnancy loss","perinatal grief","reproductive immunology","anti-phospholipid syndrom","cell-free DNA","chorionic villous sampling","RECRUITING","2025-12-07",{"date":78,"type":41},"2025-12-19",{"date":80,"type":41},"2025-10-02",{"date":82,"type":22},"2029-06",{"name":84,"class":48},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":49},"100605310","phase-4-letrozole-plus-misoprostol-versus-misoprostol-alone-for-treating-women-with-missed-miscarriage-100605310","NCT07160855","Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage","Comparison of Letrozole With Misoprostol Versus Misoprostol Alone in the Management of Missed Miscarriages","Inclusion Criteria:\n\n* Pregnant women up till 13th weeks of gestation according to last menstrual period (LMP) dates, confirmed on ultrasound\n* Single intrauterine pregnancy\n* Planned for termination due to missed miscarriage\n\nExclusion Criteria:\n\n* Previous history of cesarean section\n* Uterine scar due to previous procedure like myomectomy","45 Years",{"count":95,"type":22},92,[97],"PHASE4","The goal of this clinical trial is to learn whether adding the medicine letrozole to Misoprostol helps women have a complete abortion more often than using Misoprostol alone for the treatment of missed miscarriage (when a pregnancy has stopped developing but has not yet passed naturally).\n\nThe main questions this study aims to answer are:\n\n1. Does taking letrozole for 3 days before misoprostol increase the chance of a complete abortion compared to misoprostol alone?\n2. Does the use of letrozole affect the time it takes for abortion to occur? Who can Join? i. Women up to 13 weeks of pregnancy (based on last menstrual period and confirmed by ultrasound) who have a missed miscarriage.\n\nii. Only those with a single pregnancy are eligible. iii. Women with a previous cesarean section or uterine scar are not included.\n\nWhat Will Happen in the Study A total of 92 women will take part.\n\nParticipants will be randomly assigned to one of two groups:\n\nGroup A: Letrozole tablets once daily for 3 days, followed by one dose of vaginal misoprostol.\n\nGroup B: Placebo tablets for maximum of 3 days, followed by one dose of vaginal misoprostol.\n\nDoctors will monitor whether the abortion is complete within 24 hours. If it is not, other medical procedures will be offered as needed.\n\nProducts of conception will be examined to confirm abortion.",[28,100],"Missed Miscarriage",[102,103,104,105,106],"Abortion, missed","Abortion, induced","Letrozole","Misoprostol","first trimester","2025-08-29",{"date":109,"type":41},"2025-09-08",{"date":111,"type":41},"2025-05-13",{"date":113,"type":22},"2025-11-12",{"name":115,"class":48},"Nishtar Medical University",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":49},"100550872","phase-2-letrozole-and-misoprostol-for-early-pregnancy-loss-management-100550872","NCT06452719","Letrozole and Misoprostol for Early Pregnancy Loss Management","Letrozole and Misoprostol for Early Pregnancy Loss Management: A Prospective Pilot Cohort Study","LeMi","Inclusion Criteria:\n\n* Able to participate in the informed consent process and provide a signed and dated consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Access to working mobile phone\n* English-speaking\n* Age 18 years or older\n* Confirmed diagnosis of intrauterine embryonic\u002Ffetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure)\n\nExclusion Criteria:\n\n* Incomplete or inevitable abortion\n* Contraindication of allergy to letrozole or misoprostol\n* Unable to return for clinic-based follow-up\n* Twin or multiple pregnancy",{"count":125,"type":22},30,[127],"PHASE2","A pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a US population. Patients will be followed to assess efficacy of this treatment regimen, as well as additional interventions needed, side effects, adverse events, and patient acceptability.",[130,28,65],"Early Pregnancy Loss","2025-07-31",{"date":133,"type":41},"2025-08-05",{"date":135,"type":41},"2024-08-22",{"date":137,"type":22},"2026-07-15",{"name":139,"class":48},"University of Pennsylvania",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":49},"100599747","hysteroscopic-resection-versus-manual-vacuum-aspiration-for-early-pregnancy-100599747","NCT07088510","Hysteroscopic Resection Versus Manual Vacuum Aspiration for Early Pregnancy","A Randomized Control Trial Investigating Hysteroscopic Resection Versus Manual Vacuum Aspiration for Early Pregnancy","Inclusion Criteria:\n\n* Adult women age 18-55\n* Ultrasound Diagnosis of Early Pregnancy Loss\n* \\\u003C 9 weeks gestational age as determined by ultrasound\n* Singleton non-viable pregnancy\n* Stated and willingness to comply with all study procedures and availability for the duration of the study\n* Provision of signed and dated informed consent form\n* Chose a surgical method of management for fetal loss\n\nExclusion Criteria:\n\n* Pregnancy of Unknown Location\n* Current, viable pregnancy\n* Prior medical treatment for this early pregnancy loss\n* Contraindications to surgical management\n* Active infection (i.e. fever, chills, fundal tenderness)\n* Pre-existing coagulopathies","55 Years",{"count":149,"type":22},80,[25],"Early pregnancy loss happens when a pregnancy that is not developing properly is found on an ultrasound before 12 weeks and 6 days. This type of loss occurs in about 10% of pregnancies. There are three main ways to treat this: waiting for it to pass naturally, using medication, or having surgery. Surgery is the most effective, working 99% of the time, compared to waiting (80% effective in 8 weeks) and medication (71-84% effective). Currently, surgery involves dilation of the cervix and curettage (removal of pregnancy tissue) with suction provided either from a manual hand-held pump or a machine. For the purposes of this study, a manual vacuum aspirator (or hand-held pump) will be used with ultrasound guidance.\n\nThere is also another method called hysteroscopic resection, where the doctor uses a special camera to directly see and remove any pregnancy tissue from your uterus. Patients often want the quickest way to resolve the pregnancy loss, and physicians are unsure which surgical method is the best. It's also unclear if one type of surgery causes less scar tissue inside the uterus, affects the ability to test the tissue for genetic issues, or impacts how soon a patient can start fertility treatments again.\n\nThis study aims to find out if hysteroscopic resection provides faster resolution and creates less scar tissue compared to the manual vacuum aspiration.",[28],[154,155,156],"hysteroscopy","dilation and curettage","Manual Vacuum Aspiration","2025-07-25",{"date":159,"type":41},"2025-07-30",{"date":161,"type":41},"2025-03-31",{"date":163,"type":22},"2028-04-30",{"name":165,"class":48},"University Hospitals Cleveland Medical Center",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":172,"minAge":18,"maxAge":93,"enrollmentInfo":173,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":49},"100560787","non-invasive-monitoring-of-miscarriage-100560787","NCT06581692","Non-invasive Monitoring of Miscarriage","Inclusion Criteria:\n\n1. Age 18-45 years.\n2. Women who attend the early pregnancy loss clinic or Patients who receive ART\n3. Their partner, the biological father of the pregnancy\n\nExclusion Criteria:\n\n* History of psychological\u002F psychiatric problem\n* Patient refusal","ALL",{"count":174,"type":22},150,"cfDNA is extremely useful to ascertain chromosomal causes of miscarriages at the point of miscarriage diagnosis by a simple blood test. This study aims to determine the level of cell-free DNA (cfDNA) in early pregnancy and compare the results with those of product of conception (POC) testing, in concordance with standard karyotyping.",[28],"2024-11-11",{"date":179,"type":41},"2024-11-12",{"date":181,"type":41},"2024-09-01",{"date":183,"type":22},"2039-08-31",{"name":185,"class":48},"Chinese University of Hong Kong"]